Table 6.
Antifungal-sensitivity patterns of patients with invasive Candida infection and colonization
| Strain | Antifungal drug | Patients with invasive Candida infections | Patients with Candida Colonization | Pa | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sensitivity n (%) | MIC (μg/mL) | Sensitivity n (%) | MIC (μg/mL) | |||||||
| Range | MIC50 | MIC90 | Range | MIC50 | MIC90 | |||||
| C. albicans | AmB | 33 (100) | 0.50–1.00 | 0.50 | 0.50 | 32 (100) | 0.50–1.00 | 0.50 | 0.50 | / |
| FC | 33 (100) | 4.00–4.00 | 4.00 | 4.00 | 32 (100) | 4.00–4.00 | 4.00 | 4.00 | / | |
| Flu | 31 (93.90) | 0.50–64.00 | 1.00 | 2.00 | 32 (100) | 0.50–8.00 | 1.00 | 2.00 | 0.038 | |
| Vrc | 33 (100) | 0.06–1.00 | 0.06 | 0.06 | 32 (100) | 0.06–0.50 | 0.06 | 0.13 | / | |
| Itr | 31 (93.90) | 0.12–2.00 | 0.13 | 0.13 | 32 (100) | 0.12–0.25 | 0.13 | 0.13 | 0.038 | |
| C. glabrata | AmB | 24 (100) | 0.50–0.50 | 0.50 | 0.50 | 17 (100) | 0.50–0.50 | 0.50 | 0.50 | / |
| FC | 24 (100) | 1.00–4.00 | 4.00 | 4.00 | 16 (94.10) | 4.00–16.00 | 4.00 | 4.00 | 0.038 | |
| Flu | 24 (100) | 1.00–4.00 | 1.00 | 4.00 | 17 (100) | 1.00–8.00 | 2.00 | 8.00 | / | |
| Vrc | 23 (95.80) | 0.06–2.00 | 0.06 | 0.25 | 17 (100) | 0.06–0.50 | 0.06 | 0.50 | 0.130 | |
| Itr | 19 (79.20) | 0.12–0.50 | 0.13 | 0.50 | 9 (52.90) | 0.12–2.00 | 0.13 | 1.00 | <0.001 | |
| C. tropicalis | AmB | 11 (100) | 0.50–1.00 | 0.50 | 1.00 | 8 (100) | 0.50–1.00 | 0.50 | 1.00 | / |
| FC | 11 (100) | 4.00–4.00 | 4.00 | 4.00 | 8 (100) | 4.00–4.00 | 4.00 | 4.00 | / | |
| Flu | 7 (63.60) | 0.50–128.00 | 2.00 | 64.00 | 7 (87.50) | 1.00–64.00 | 1.00 | 64.00 | <0.001 | |
| Vrc | 9 (81.80) | 0.06–8.00 | 0.13 | 4.00 | 7 (87.50) | 0.06–4.00 | 0.06 | 4.00 | 0.314 | |
| Itr | 6 (54.50) | 0.12–4.00 | 0.13 | 2.00 | 7 (87.50) | 0.12–2.00 | 0.13 | 2.00 | <0.001 | |
| C. parapsilosis | AmB | 6 (100) | 0.50–0.50 | 0.50 | 0.50 | 1 (100) | / | 0.50 | 0.50 | / |
| FC | 6 (100) | 4.00–4.00 | 4.00 | 4.00 | 1 (100) | / | 4.00 | 4.00 | / | |
| Flu | 5 (83.30) | 1.00–64.00 | 4.00 | 64.00 | 1 (100) | / | 4.00 | 4.00 | / | |
| Vrc | 5 (83.30) | 0.06–2.00 | 0.06 | 2.00 | 1 (100) | / | 0.13 | 0.13 | / | |
| Itr | 4 (66.70) | 0.12–0.50 | 0.13 | 0.50 | 1 (100) | / | 0.13 | 0.13 | / | |
| C. krusei | AmB | 1 (100) | / | 0.50 | 0.50 | / | / | / | / | / |
| FC | 1 (100) | / | 4.00 | 4.00 | / | / | / | / | / | |
| Flu | / | / | / | / | / | / | / | / | / | |
| Vrc | 1 (100) | / | 0.06 | 0.06 | / | / | / | / | / | |
| Itr | / | / | / | / | / | / | / | / | / | |
Notes: aComparisons of the indicated antifungal sensitivities between the two cohorts in terms of the percentage of Candida strains, except colonized C. parapsilosis and C. krusei.
Abbreviations: AmB, amphotericin B; FC, 5-fluorocytosine; Flu, fluconazole; Vrc, voriconazole; Itr, itraconazole; MIC, minimum inhibitory concentration.